Melatonin, refractory hypertension, myocardial ischemia and other challenges in nightly blood pressure lowering

Zaslavskaya, R. M.; Lilitsa, G.; Dilmagambetova, G. S.; Halberg, Franz; Cornélissen, Germaine; Otsuka, Kuniaki; Singh, Ram B.; Stoynev, Alexander; Ikonomov, Ognian C.; Tarquini, Roberto; Perfetto, Federico; Schwartzkopff, Othild; Bakken, Earl E.

doi:10.1016/s0753-3322(04)80021-0

Cited by 12 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zaslavskaya et al. (92) studied melatonin effects on contractile myocardial function; patients with postmyocardial infarction and heart failure, assessed as stage II‐III by New York Heart Association (NYHA). They found melatonin associated anti‐anginal and anti‐ischaemic effects, indicating improvement of contractile function.…”

Section: Cardiovascular Diseasesmentioning

confidence: 99%

“…Combined treatment with insulin and melatonin can suppress hyperglycaemia, prevent oxidative damage and can restore endothelial function completely, implying that treatment of diabetes mellitus with this combination would be beneficial. Zaslavskaya et al (92) studied melatonin effects on contractile myocardial function; patients with postmyocardial infarction and heart failure, assessed as stage II-III by New York Heart Association (NYHA). They found melatonin associated anti-anginal and anti-ischaemic effects, indicating improvement of contractile function.…”

Section: Cardiovascular Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Melatonin: therapeutic and clinical utilization

Altun¹,

Uğur-Altun

2007

International Journal of Clinical Practice

193

114

View full text Add to dashboard Cite

Melatonin, acting through melatonin receptors, is involved in numerous physiological processes including circadian entrainment, blood pressure regulation, oncogenesis, retinal physiology, seasonal reproduction, ovarian physiology, immune function and most recently in inducing osteoblast differentiation. Moreover, melatonin was proved to be a potent-free radical scavenger and a broad-spectrum antioxidant. More research is required into the effects of therapeutically modulating the melatoninergic system on circadian haemodynamics and rhythm under varying physiopathological conditions and the possible impact on morbidity and mortality in humans.

show abstract

Section: Cardiovascular Diseasesmentioning

confidence: 99%

Section: Cardiovascular Diseasesmentioning

confidence: 99%

Melatonin: therapeutic and clinical utilization

Altun¹,

Uğur-Altun

2007

International Journal of Clinical Practice

193

114

View full text Add to dashboard Cite

show abstract

“…Lower DBP and lower hematocrit may therein be the most possible pathophysiological mechanisms for the deleterious effects of UGIH on those who are taking aspirin for CAD. It has also been demonstrated that lower DBP is strongly associated with myocardial ischemia because of reduced coronary perfusion 9,10 . However, lower hematocrit always indicates the severity of anemia, which in turn has been proven to be associated with graver outcomes for those with CAD, whereas maintenance of adequate hematocrit may provide protective benefits 11–13 …”

Section: Discussionmentioning

confidence: 99%

Silent myocardial ischemia in coronary artery disease patients under aspirin therapy presenting with upper gastrointestinal hemorrhage

Chen

Chong

Kuo³

et al. 2006

J of Gastro and Hepatol

View full text Add to dashboard Cite

Myocardial ischemia is a relatively common complication in CAD patients under aspirin therapy presenting with upper gastrointestinal hemorrhage. A history of CAD with triple vessel disease, higher blood urea nitrogen, lower diastolic blood pressure and lower hematocrit may help identify patients who are at increased risk of myocardial ischemia, which tends to be associated with higher in-hospital mortality and increased length of hospital stay.

show abstract

“…In addition, as β‐blockers inhibit melatonin secretion, melatonin supplementation improves sleep in hypertensive patients treated with β‐blockers . Melatonin has also been tested as an adjuvant in the treatment of refractory hypertension, with some positive results .…”

Section: Non‐nutrient Nutraceuticalsmentioning

confidence: 99%

Nutraceuticals with a clinically detectable blood pressure‐lowering effect: a review of available randomized clinical trials and their meta‐analyses

Borghi

Cicero

2016

Brit J Clinical Pharma

105

View full text Add to dashboard Cite

AIMSThe aim of the present study was to review and comment on the available evidence on nutraceuticals with a clinically demonstrable blood pressure (BP)-lowering effect. METHODSWe reviewed studies published in the English language from 1990 to 2015 on dietary supplements or nutraceuticals claiming to show an effect on human BP. An initial list of possibly effective agents and studies was obtained from the online reference, the Natural Medicine Comprehensive Database. Using PubMed, we searched agents identified from this list using the MeSH terms 'hypertension', 'blood pressure', 'dietary supplement' and 'nutraceuticals', alone and in combination. We then focused our attention on meta-analyses and randomized clinical trials. RESULTSBeyond the well-known effects on BP of the Dietary Approaches to Stop Hypertension (DASH) and the Mediterranean diet, a large number of studies have investigated the possible BP-lowering effect of different dietary supplements and nutraceuticals, most of which are antioxidant agents with a high tolerability and safety profile. In particular, a relatively large body of evidence supports the use of potassium, magnesium, L-arginine, vitamin C, cocoa flavonoids, beetroot juice, coenzyme Q10, controlled-release melatonin and aged garlic extract. The antihypertensive effect of all these nutraceuticals seems to be dose related and the overall tolerability is good. CONCLUSIONSome nutraceuticals might have a positive impact on BP in humans. Further clinical research is needed, to identify from the available active nutraceuticals those with the best cost-effectiveness and risk-benefit ratio for widespread and long-term use in the general population with a low-added cardiovascular risk related to uncomplicated hypertension.

show abstract

Melatonin, refractory hypertension, myocardial ischemia and other challenges in nightly blood pressure lowering

Cited by 12 publications

References 11 publications

Melatonin: therapeutic and clinical utilization

Melatonin: therapeutic and clinical utilization

Silent myocardial ischemia in coronary artery disease patients under aspirin therapy presenting with upper gastrointestinal hemorrhage

Nutraceuticals with a clinically detectable blood pressure‐lowering effect: a review of available randomized clinical trials and their meta‐analyses

Contact Info

Product

Resources

About